 This study is designed to assess the safety of the approved and licensed HUMENZA adjuvanted AH1N1 pandemic influenza vaccine and PANENZA non-adjuvanted AH1N1 pandemic influenza vaccine to meet regulatory requirements for post-marketing safety monitoring. 